{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:57:41Z","timestamp":1781308661341,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["75D30122D15431"],"award-info":[{"award-number":["75D30122D15431"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["75D30122F00001"],"award-info":[{"award-number":["75D30122F00001"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128460","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:02:11Z","timestamp":1773334931000},"page":"128460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65\u00a0years and older"],"prefix":"10.1016","volume":"79","author":[{"given":"Rowan","family":"McEvoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Rose","family":"Hervol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnstein","family":"Lindaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vennis","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Quincer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoganand","family":"Chillarige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128460_bb0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.puhe.2021.02.025","article-title":"Vaccine hesitancy in the era of COVID-19","volume":"194","author":"Troiano","year":"2021","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2026.128460_bb0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl J Med."},{"key":"10.1016\/j.vaccine.2026.128460_bb0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128460_bb0035","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128460_bb0040","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"New Engl J Med."},{"key":"10.1016\/j.vaccine.2026.128460_bb0045","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/S0140-6736(22)00791-7","article-title":"Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases","volume":"399","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128460_bb0050","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/j.vaccine.2022.07.007","article-title":"Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination","volume":"40","author":"Goddard","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128460_bb0055","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the vaccine adverse event reporting system and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128460_bb0060","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128460_bb0065","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.15585\/mmwr.mm7043e2","article-title":"COVID-19 vaccination and non-COVID-19 mortality risk - seven integrated health care organizations, United States, December 14, 2020-July 31, 2021","volume":"70","author":"Xu","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128460_bb0070","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.vaccine.2022.12.036","article-title":"A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination","volume":"41","author":"Xu","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128460_bb0075","author":"Florida Department of Health"},{"key":"10.1016\/j.vaccine.2026.128460_bb0080","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.vaccine.2024.02.032","article-title":"Mortality risk after COVID-19 vaccination: a self-controlled case series study","volume":"42","author":"Xu","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128460_bb0085","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128460_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2307\/2533328","article-title":"Relative incidence estimation from case series for vaccine safety evaluation","volume":"51","author":"Farrington","year":"1995","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2026.128460_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/biostatistics\/kxn013","article-title":"Case series analysis for censored, perturbed, or curtailed post-event exposures","volume":"10","author":"Farrington","year":"2009","journal-title":"Biostat"},{"key":"10.1016\/j.vaccine.2026.128460_bb0100","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/sim.9325","article-title":"A modified self-controlled case series method for event-dependent exposures and high event-related mortality, with application to COVID-19 vaccine safety","volume":"41","author":"Ghebremichael-Weldeselassie","year":"2022","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128460_bb0125","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/pds.4421","article-title":"Development of algorithms for identifying fatal cardiovascular disease in Medicare claims","volume":"27","author":"Xie","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128460_bb0135","author":"Schwarzer"},{"key":"10.1016\/j.vaccine.2026.128460_bb0140","author":"Yonas Ghebremichael Weldeselassie"},{"key":"10.1016\/j.vaccine.2026.128460_bb0145","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1016\/j.vaccine.2022.08.039","article-title":"Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study","volume":"40","author":"Stivanello","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128460_bb0150","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41467-023-36494-0","article-title":"Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England","volume":"14","author":"Nafilyan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128460_bb0155","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S0950268811001531","article-title":"Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice","volume":"139","author":"Weldeselassie","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2026.128460_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273196","article-title":"Assessment of performance characteristics of COVID-19 ICD-10-CM diagnosis code U07.1 using SARS-CoV-2 nucleic acid amplification test results","volume":"17","author":"Moll","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128460_bb0165","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/sim.4125","article-title":"Identifying optimal risk windows for self-controlled case series studies of vaccine safety","volume":"30","author":"Xu","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128460_bb0170","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/sim.5733","article-title":"A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design","volume":"32","author":"Xu","year":"2013","journal-title":"Stat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:52:37Z","timestamp":1781308357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S0264410X26002689"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128460","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65\u00a0years and older","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128460"}}